Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China flag China · Delayed Price · Currency is CNY
53.00
-0.82 (-1.52%)
At close: Feb 6, 2026
25.30%
Market Cap24.63B +51.6%
Revenue (ttm)607.75M +56.0%
Net Income-867.44M
EPS-2.00
Shares Out464.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,870,420
Average Volume3,149,050
Open53.25
Previous Close53.82
Day's Range52.52 - 54.01
52-Week Range40.67 - 86.18
Beta0.09
RSI32.75
Earnings DateMar 31, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of cancer and immunological diseases. Its assets include the ZEGFROVY, for the treatment of solid tumors; Golidocitinib to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. The company was founded in 2017 and is based in Shan... [Read more]

Sector Healthcare
Founded 2017
Employees 985
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688192
Full Company Profile

Financial Performance

In 2024, SHA:688192's revenue was 359.90 million, an increase of 294.24% compared to the previous year's 91.29 million. Losses were -845.96 million, -23.63% less than in 2023.

Financial Statements